No Data
Jim Cramer on Bristol-Myers Squibb Company (BMY): 'I Think It's A Great Time To Consider Buying This One'
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Arthur J. Gallagher, TC Energy and Bridger Aerospace
With 77% Institutional Ownership, Bristol-Myers Squibb Company (NYSE:BMY) Is a Favorite Amongst the Big Guns
Bristol-Myers Squibb: Hold Rating With Anticipated Revenue Outperformance Offset by Generic Competition Concerns
The combination therapy of nivolumab and ipilimumab from bristol-myers squibb (BMY.US) has been approved in China.
On October 14, Bristol-Myers Squibb (BMY.US) announced that its 'Dual Immune Checkpoint Therapy' application for the combination of Nivolumab and Ipilimumab has been approved by the China National Medical Products Administration (NMPA).
ExpandNo Data
No Data
103811615 : Nyi Nyi Htwe Y324412